Antibiotics

Lingering historical concerns have led to inconsistent practices in antibiotic prophylaxis in this population.

Poignant study adds to the growing body of literature that points toward individualizing duration of therapy for each patient.

Dr. Richard Vickers, discusses C. difficile rates in the United Kingdom.

One successful model takes an engineering approach to patient safety outcomes focusing on work system improvements.

FDA recommends that health care providers practice caution before prescribing clarithromycin to patients with heart disease due to potentially fatal long-term risks.

One agency estimates that at least 50% of all antibiotic prescriptions written in the United States do not fall under currently accepted practice guidelines.

Efforts to curb antimicrobial resistance have hit a brick wall in India, where new research finds unapproved drug combinations are rampant.

Dr. Richard Vickers, discusses what the next steps are for Summit Therapeutic’s ridinilazole.

Marin H. Kollef, MD, discusses what to consider when calling for cultures.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

The broad-spectrum investigational antibiotic has been developed for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Superbugs resistant to colistin – a last-resort antibiotic – may have a new foe in octapeptins, antibiotics discovered decades ago that recently have been found to be effective against multidrug-resistant gram-negative bacteria.

The Cystic Fibrosis Foundation has awarded Motif Bio with $120,000 that will fund in vitro testing for the development of iclaprim to benefit patients with cystic fibrosis who have lung infections.

The FDA has approved Allergan's sNDA to expand the approved use of AVYCAZ (ceftazidime and avibactam), to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms.